Patent classifications
C07D213/12
Combination pharmaceutical agents as RSV inhibitors
The present invention relates to a pharmaceutical composition useful for treating a Respiratory Syncytial Virus (RSV) infection, comprising a compound which is ##STR00001##
or a pharmaceutically acceptable salt thereof, and a second anti-respiratory syncytial virus agent.
Substituted 4-aminocyclohexane derivatives
The invention relates to compounds that have an affinity to the -opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.
Substituted 4-aminocyclohexane derivatives
The invention relates to compounds that have an affinity to the -opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.
Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
The present invention comprises compounds and compositions thereof for enhanced drug delivery. Pro-drug and double pro-drug derivatives of corticosteroids non-steroid anti-inflammatory drugs (NSAIDs), and ruboxistaurin for delivery to the eye are provided. The compounds and compositions are useful for treating various ocular diseases, including ocular diseases effecting the posterior segments of the eye. In addition, the present invention is directed to particle in particle carrier formulations for sustained release of therapeutic agents.
CATALYST
A compound of formula (I-A), R.sup.1 in each occurrence is selected from H, optionally substituted C.sub.1-12 alkyl and optionally substituted C.sub.6-20 aryl; R.sup.2 in each occurrence is selected from optionally substituted C.sub.1-12 alkyl and optionally substituted C.sub.6-20 aryl; p is 1 and q is 5 or pis 2 and q is 4; p+q=6; Y is an anion; and n is 1 or 2. The compounds of formula (I-A) may be used to catalyse reactions including arylation and alkylation at the carbon atom of a CH group in which the C atom is sp.sup.2-hybridised.
##STR00001##
Heterocyclic inhibitors of MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: ##STR00001## Methods of inhibition MCT4 activity in a human or animal subject are also provided.
Heterocyclic inhibitors of MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: ##STR00001## Methods of inhibition MCT4 activity in a human or animal subject are also provided.
HETEROCYCLIC INHIBITORS OF MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:
##STR00001##
Methods of inhibition MCT4 activity in a human or animal subject are also provided.
HETEROCYCLIC INHIBITORS OF MCT4
Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:
##STR00001##
Methods of inhibition MCT4 activity in a human or animal subject are also provided.
Air-stable ni(0)-olefin complexes and their use as catalysts or precatalysts
The present invention relates to air stable, binary Ni(0)-olefin complexes and their use in organic synthesis.